newsfilter
← Latest News
Business Wire·

Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

A

Test enables identification of patients whose tumors express PD-L1 and who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® Agilent Technologies Inc. (NYSE:A) today announced that it has